Core Viewpoint - Recently, a new investment partnership named Zhongjin (Zhangzhou) Medical Industry Investment Partnership (Limited Partnership) was established with a capital of 1 billion yuan, focusing on investment activities using its own funds [1] Group 1: Company Information - The new partnership is co-funded by Pianzaihuang's wholly-owned subsidiary Zhangzhou Pianzaihuang Investment Management Co., Ltd. and Zhongjin Company's wholly-owned subsidiary Zhongjin Capital Operation Co., Ltd. [1]

| 全国企业信用查询 | | 中金（漳州）医疗产业投资合伙企业（有限合: 8 | 查一下 | | --- | --- | --- | --- | | 基本信息 13 | 法律诉讼 | 经营风险 | 经营信息 | | 执行事务合伙人 | 中金资本运营有限公司 | 登记状态 | 存续（在营、开业、 | | | | 出资额 | 100000万元 | | 组织机构代码 | MAEX7643-7 | 工商注册号 | 350606110422600 | | 企业类型 | 有限合伙企业 | 营业期限 | 2025-10-14 至 无固ｽ | | 人员规模 | l | 参保人数 | | | 所属地区 | 福建省漳州市龙海区 | 登记机关 | 漳州高新技术产业开 | | 国标行业 | 资本市场服务（J67）∨ | 英文名 | CICC (Zhangzhou) M 自动翻译更新) | | 主要经营场所 | | 福建省漳州市龙海区颜厝镇龙江大街12号龙江新苑SY9幢D01室（邮编363100 | | | 经营范围 | | 一般项目：以自有资金从事投资活动。（除依法须经批准的项目外，凭营业执脱 | | | 国企业信用查询 | 中金 ...

9月30日，深耕医疗投资领域十余载的约印医疗基金，迎来发展历程中的关键里程碑——其第五期人民 币综合基金"约印新源（成都）股权投资合伙企业（有限合伙）"，正式完成中国证券投资基金业协会备 案手续，并同步启动对外投资工作。据悉，该基金总规模达15亿元人民币，出资方阵容堪称行业标杆， 汇聚了成都市交子产业基金及高新区策源资本、北京经开区政府投资产业引导基金、横琴粤澳深度合作 区产业投资基金、无锡惠山经济技术开发区引导基金、江西赣江新区现代产业引导基金、启东金北翼母 基金等七家来自全国核心区域的顶尖央、国企机构。 此次资本联动横跨成渝、京津冀、粤港澳大湾区、长三角及中部核心经济圈四大核心经济区，不仅为约 印医疗基金的专业投资能力提供了权威背书，更标志着"国资力量+专业投资机构"协同赋能医疗产业创 新的模式探索，成功迈出关键性一步。 十年磨一剑：构建"投融退"闭环，约印医疗基金的投资方法论 能吸引全国核心区域国资机构集体入局，约印医疗基金的成功并非偶然。自2015年成立以来，其在医疗 投资赛道持续深耕，逐步沉淀出"投得准、陪得好、退得出"的完整投资逻辑，这正是产业伙伴与被投企 业选择与之深度合作的核心基石。 在投资判 ...

Core Viewpoint - Betta Pharmaceuticals (300957.SZ) aims to enhance its comprehensive competitiveness and profitability by becoming a limited partner in a new investment fund focused on the healthcare sector [1] Group 1: Investment Details - The company will invest 50 million yuan as a limited partner in the Wuxi Jinyu Maowu Medical Health Industry Investment Partnership, holding a 5% share in the fund [1] - The fund is established in collaboration with several partners, including Wuxi Jinjiao Investment Partnership and Jiangsu Wuxi Biomedical Industry Special Mother Fund [1] Group 2: Investment Focus - The partnership will primarily invest in areas such as consumer healthcare, quality improvement of national health, pharmaceuticals (including synthetic biology and innovative drugs), medical devices, supportive medical industries, and AI-driven pharmaceuticals [1]

Core Viewpoint - Betta Pharmaceuticals (300957.SZ) aims to enhance its comprehensive competitiveness and profitability by becoming a limited partner in a new investment fund focused on the healthcare industry [1] Group 1: Investment Details - The company will invest 50 million yuan as a limited partner in the Wuxi Jinyu Maowu Medical Health Industry Investment Partnership, holding a 5% share in the fund [1] - The fund is established in collaboration with several partners, including Wuxi Jinjiao Investment Partnership and Jiangsu Wuxi Biomedical Industry Special Mother Fund [1] Group 2: Investment Focus - The partnership will primarily invest in sectors such as consumer healthcare, quality improvement of national health, pharmaceuticals (including synthetic biology and innovative drugs), medical devices, supportive medical industries, and AI-driven pharmaceuticals [1]

Core Viewpoint - Betaini (300957) has signed a partnership agreement with Wuxi Jinyu Maowu Medical Health Industry Investment Partnership, committing 50 million yuan as a limited partner, acquiring a 5% stake in the fund [1] Investment Details - The investment will focus on sectors such as consumer healthcare, national health quality improvement (including wellness, medical aesthetics, special medical foods, and functional foods), pharmaceuticals (including synthetic biology and innovative drugs), medical devices, supportive medical industries, and AI in pharmaceuticals [1]

Core Viewpoint - Betta Pharmaceuticals (300957.SZ) has signed a partnership agreement with Wuxi Jinyu Maowu Medical Health Industry Investment Partnership, committing 50 million yuan as a limited partner, acquiring a 5% stake in the fund [1] Investment Focus - The partnership will primarily invest in sectors such as consumer healthcare, national health quality improvement (including wellness, medical aesthetics, special medical foods, and functional foods), pharmaceuticals (including synthetic biology and innovative drugs), medical devices, supportive medical industries, and AI-driven pharmaceuticals [1]

Core Viewpoint - Kangqiao Capital appointed Wu Yifang as Executive Operating Partner, bringing extensive experience from Fosun International and Fosun Pharma [1] Group 1 - Wu Yifang previously served as the Executive Vice President of Fosun International [1] - Wu held the position of Chairman and CEO of Fosun Pharma for nearly ten years [1] - The appointment is expected to enhance Kangqiao Capital's operational capabilities [1]

Core Viewpoint - Shanghai Kangdelai Enterprise Development Group Co., Ltd. is undergoing a share transfer, reducing the stake held by Shanghai Kangdelai Holding Group Co., Ltd. from 39.58% to 34.58% through an agreement transfer of 21,839,544 shares to Changsha Medical Investment Co., Ltd. [1][6][12] Group 1: Share Transfer Details - The share transfer involves 21,839,544 shares, representing 5% of the total share capital of the company [6][7] - The transfer price is set at RMB 10.81 per share, totaling RMB 236,085,470.64 [7] - The payment structure includes an initial 50% payment of RMB 118,042,735.32 within 10 working days of signing the agreement, with the remaining amount due within 3 working days after the transfer is completed [7][8] Group 2: Purpose and Future Plans - The purpose of the share transfer is to enhance the strategic layout of the company and improve its valuation and competitiveness in the healthcare industry [6][12] - There are currently no plans for the information disclosure obligor to increase or decrease its stake in the company within the next 12 months, aside from this transfer [6][12] Group 3: Compliance and Legal Aspects - The share transfer is subject to compliance confirmation from the Shanghai Stock Exchange and must be registered with the China Securities Depository and Clearing Corporation [8][9] - The information disclosure obligor has committed to the accuracy and completeness of the report and assumes legal responsibility for any misrepresentation [2][10]

Group 1 - The company has approved the liquidation and deregistration of the Nanjing New Industry Medical Investment Fund Partnership, which will distribute the remaining assets according to the partners' paid-in capital ratio [1] - The fund has obtained the registration notice from the Nanjing Yuhuatai District Administrative Service Management Office, completing the deregistration process [1] - The fund will no longer be included in the company's consolidated financial statements [1] Group 2 - The liquidation of the fund will not adversely affect the company's overall business development or profitability, and there is no harm to the interests of the company and all shareholders [2]